Get the Stockscreener App
1.94
2.11%
0.04
After Hours:
1.94
Cytomed Therapeutics Ltd stock is traded at $1.94, with a volume of 8,702.
It is up +2.11% in the last 24 hours and down -16.74% over the past month.
CytoMed Therapeutics Ltd is a pre-clinical biopharmaceutical company focused on harnessing its proprietary technologies to create novel cell-based immunotherapies for the treatment of human cancers. The company's segment include: the business of innate immune cell-based immunotherapy, pluripotent stem cell-based therapy and undertaking the research and development of immune cell and stem cell-based therapy; and the business of processing and banking of cells including cord blood stem cells, research and development on cord blood derived cell-based therapy. Geographically, the company operates in Singapore and Malaysia which is the majority revenue generator.
See More
Previous Close:
$1.90
Open:
$1.93
24h Volume:
8,702
Relative Volume:
0.80
Market Cap:
$21.93M
Revenue:
-
Net Income/Loss:
$-3.15M
P/E Ratio:
-6.3565
EPS:
-0.3052
Net Cash Flow:
$-2.23M
1W Performance:
-3.96%
1M Performance:
-16.74%
6M Performance:
-24.22%
1Y Performance:
+14.12%
1-Day Range:
$1.887
$1.95
1-Week Range:
$1.85
$1.965
52-Week Range:
$1.20
$4.0499
Cytomed Therapeutics Ltd Stock (GDTC) Company Profile
Name
Cytomed Therapeutics Ltd
Sector
Industry
Phone
-
Address
-
Compare GDTC with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GDTC
Cytomed Therapeutics Ltd
|
1.94 | 21.93M | 0 | -3.15M | -2.23M | -0.3052 |
|
VRTX
Vertex Pharmaceuticals Inc
|
468.41 | 118.34B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
558.14 | 60.31B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
330.55 | 42.35B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
598.79 | 36.43B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
305.74 | 31.87B | 3.81B | -644.79M | -669.77M | -6.24 |
Cytomed Therapeutics Ltd Stock (GDTC) Latest News
Published on: 2025-07-29 02:23:22 - metal.it
What is the risk reward ratio of investing in CytoMed Therapeutics Limited stockUnrivaled growth potential - jammulinksnews.com
Price momentum metrics for CytoMed Therapeutics Limited explainedTechnical Trade Plan with Entry Checklist - Newser
Does CytoMed Therapeutics Limited stock perform well during market downturnsCapitalize on trading strategies that deliver - jammulinksnews.com
What are analysts’ price targets for CytoMed Therapeutics Limited in the next 12 monthsCapitalize on fast-moving stock opportunities - jammulinksnews.com
CytoMed Therapeutics Limited Stock Analysis and ForecastMarket-leading growth rates - Autocar Professional
What drives CytoMed Therapeutics Limited stock priceExplosive market performance - jammulinksnews.com
Is CytoMed Therapeutics Limited a good long term investmentRapid-fire capital growth - jammulinksnews.com
How high can CytoMed Therapeutics Limited stock price go in 2025Daily Swing Candidates - Newser
What drives SDST stock priceConsistently profitable trades - Autocar Professional
The ANGELICA Trial and the Future of Allogeneic CAR-T: A Strategic Investment Perspective - AInvest
CytoMed's Breakthrough Cancer Cell Therapy Shows Promise in Phase 1 Trial, Advances to Higher Dose Testing - Stock Titan
GDTC advances CTM-N2D: Dose Level 1 complete, Phase I escalates | GDTC SEC FilingForm 6-K - Stock Titan
COST Stock Analysis and ForecastFree Investment Community - jammulinksnews.com
Blue Chip Stocks High Precision Stock TipsBreakthrough stock performance - jammulinksnews.com
What analysts say about CytoMed Therapeutics Limited stockExceptional profit velocity - jammulinksnews.com
How CytoMed Therapeutics Limited stock performs during market volatilitySmart Money Trade Setups - Newser
What makes CytoMed Therapeutics Limited stock price move sharplySafe and Scalable Investment Tips - Newser
Why CytoMed Therapeutics Limited stock attracts strong analyst attentionTrade With Low Risk Exposure - Newser
CytoMed Therapeutics shareholders approve all proposals at annual meeting By Investing.com - Investing.com Nigeria
CytoMed Therapeutics shareholders approve all proposals at annual meeting - Investing.com
The Pipeline for of iPSC-Derived Cell Therapeutics in 2025 - BioInformant
Cytomed Therapeutics (GDTC) Files for $50M Mixed Securities Shel - GuruFocus
CytoMed Therapeutics Files $50 Million Mixed Shelf - MarketScreener
Cytomed Therapeutics (GDTC) Files for $50M Mixed Securities Shelf Offering | GDTC Stock News - GuruFocus
CytoMed Therapeutics schedules annual shareholder meeting - Investing.com Australia
CytoMed Therapeutics schedules annual shareholder meeting By Investing.com - Investing.com India
CytoMed Therapeutics (NASDAQ:GDTC) Stock Price Down 0.4% – Here’s Why - Defense World
CytoMed Therapeutics Full Year 2024 Earnings: Revenues Beat Expectations, EPS Lags - Yahoo Finance
Interview with the Chairman: CytoMed Therapeutics Ltd. (NASDAQ:GDTC) - The Wall Street Transcript
CytoMed Therapeutics Reports Full Year Ended December 31, - GlobeNewswire
CytoMed 2024 Results: 39% Lower Losses as Biotech Advances Novel Cancer Cell Therapy Trial - Stock Titan
Cytomed Therapeutics Ltd shares rise 3.08% intraday after Osteopore secures EU approval for custom orthopaedic and cranial implants. - AInvest
Graft Versus Host Disease Market is Projected for Substantial Expansion from USD 1.3 Billion in 2023| DelveInsight - The Globe and Mail
Microbiome Disease Clinical Trial Analysis: Key Insights into Rich Pipeline Featuring 140+ Companies and 180+ Therapies | DelveInsight - GlobeNewswire
CytoMed Diversifies into Regenerative Medicine after Research Collaboration with Singapore's Sengkang General Hospital to Test Injectable Umbilical Cord-Derived Mesenchymal Stem Cells for Cartilage Regeneration - ACCESS Newswire
CytoMed Therapeutics announces Chairman’s Letter to the Company’s shareholders - Marketscreener.com
SunAct Cancer Institute and CytoMed begin phase 2 trials for Gamma Delta T-cell therapy - Express Healthcare
SunAct Cancer Institute ties up with Singapore’s CytoMed for phase 2 clinical trials on innovative Gamma Delta T-cell cancer therapy in India - Pharmabiz.com
CytoMed Partners with SunAct for Groundbreaking Cancer Cell Therapy Trial in India - Stock Titan
CytoMed Therapeutics Leads 3 US Penny Stocks To Consider - simplywall.st
CytoMed Therapeutics And 2 Other US Penny Stocks To Watch - Yahoo Finance
Update on Clinical MilestoneCytoMed Therapeutics Announces First Patient Dosed in its First-in-Human Phase I Clinical Trial of Allogeneic CAR-Gamma Delta T Cell Therapy in Patients with Advanced Solid Tumours or Haematological Malignancies - Yahoo Finance
CytoMed Therapeutics Acquires Cord Blood Banking License and 12,000 CBUs; Will Develop Cord Blood-derived Biologics through It Subsidiary, LongevityBank - BioInformant
Discovering Penny Stocks On US Exchanges: 3 Picks Under $100M Market Cap - Yahoo Finance
Osteopore partners with NASDAQ-listed CytoMed to advance MSC-powered regeneration - Biotech Dispatch
CytoMed Therapeutics’ first-in-human Phase I ANGELICA clinical trial using its patented donor allogeneic chimeric antigen receptor T cell (CAR-T cell) against blood and solid tumors received co-funding support from the NMRC Clinical Trial Grant - GlobeNewswire
CytoMed Therapeutics completes cash acquisition of Cord - GlobeNewswire
CytoMed Therapeutics Reports Six Months Ended June 30, 2024 - GlobeNewswire
iPSC Applications in Cell Therapy, Drug Discovery, and Beyond - BioInformant
CytoMed Therapeutics Acquires Cord Blood Banking Licence and Assets to Entrench Its Strategy in Allogeneic, Off-the-shelf Donor-derived Gamma Delta (γδ) T Cells Technology for Solid and Liquid Cancers - GlobeNewswire
Cytomed Therapeutics Ltd Stock (GDTC) Financials Data
Revenue
Net Income
Cash Flow
EPS
10.28%
2.59%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):